Treatment of Lambert-Eaton myasthenic syndrome with 3,4-diaminopyridin

Treatment of Lambert-Eaton myasthenic syndrome with 3,4-diaminopyridin - Treatment of LEMS with diaminopyridin

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004795

Enrollment

Registered

2011-01-04

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lambert-Eaton myasthenic syndrome

Interventions

3,4-diaminopyridine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who are histopathologically diagnosed as lung cancer. 2) Patients who are electrically diagnosed to have Lambert-Eaton myasthenic syndrome. 3) Patients who are informed of their diagnosis. 4) Patients who do not have history of seizure or epilepsy. 5) Patients who agreed to participate in the present study by written informed consent.

Exclusion criteria

Exclusion criteria: Patients who are not able to comprehend the aim of the present study due to brain metastasis or metabolic encephalopathy are excluded.

Design outcomes

Primary

Measure	Time frame
Neurological findings, Barthel Index, compound motor action potentials and waxing rate on nerve conduction studies conducted 1, 2, 4 months after treatment.	—

Countries

Japan

Contacts

Public ContactShunsuke Kobayashi

Fukushima Medical University Department of Neurology

skoba66@fmu.ac.jp024-547-1248

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026